Blog

L3Harris Technologies, Inc. (NYSE:LHX) is among the 10 Largest Defense Stocks in 2025. On October 20, the company announced that it had been selected by the Republic of Korea for its airborne early warning and control (AEW&C) program.

Under the contract, the firm will partner with Bombardier, Korean Air, and ELTA Systems to deliver modified Bombardier Global 6500 AEW&C aircraft for the country’s air force. The program is valued at over $2.26 billion.

The advanced aircraft fleet will operate longer and fly faster, aiding in enhancing Korea’s mission readiness. The aircraft will also cruise at higher altitudes, providing combat-proven radar coverage and improved security, which will aid in swift detection and tackling of threats. Moreover, the communications suite will offer interoperability with the US, NATO, and other allied partners, resulting in a networked battlespace.

Christopher Kubasik, Chair and CEO, at L3Harris Technologies, Inc. (NYSE:LHX) shared the following remarks on the contract award:

“L3Harris is ready to deliver an advanced aircraft fleet that will strengthen mission effectiveness for a key American ally in the Indo-Pacific region. We look forward to collaborating with the Republic of Korea to develop, test, integrate and sustain this vital capability for years to come.”

L3Harris Technologies, Inc. (NYSE:LHX) provides end-to-end technology solutions connecting the air, land, space, sea, and cyber domains in national security. The stock has delivered impressive returns in 2025, rising over 42% year-to-date as of October 23.

While we acknowledge the potential of LHX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 14 Best Big Name Stocks to Invest in Right Now and 9 Defense Stocks That Will Skyrocket

Disclosure: None.

Please chooseI’m not a medical professional.Allergy and ImmunologyAnatomyAnesthesiologyBiostatisticsCardiac/Thoracic/Vascular SurgeryCardiologyCritical CareDentistryDermatologyDiabetes and EndocrinologyEmergency MedicineEpidemiology and Public HealthFamily MedicineForensic MedicineGastroenterologyGeneral PracticeGeneticsGeriatricsHealth PolicyHematologyHIV/AIDSHospital-based MedicineI’m not a medical professional.Infectious DiseaseIntegrative/Complementary MedicineInternal MedicineInternal Medicine-PediatricsMedical Education and SimulationMedical PhysicsMedical StudentNephrologyNeurological SurgeryNeurologyNuclear MedicineNutritionObstetrics and GynecologyOccupational HealthOncologyOphthalmologyOptometryOral MedicineOrthopaedicsOsteopathic MedicineOtolaryngologyPain ManagementPalliative CarePathologyPediatricsPediatric SurgeryPharmacologyPhysical Medicine and RehabilitationPlastic SurgeryPodiatryPreventive MedicinePsychiatryPsychologyPulmonologyRadiation OncologyRadiologyRheumatologySubstance Use and AddictionSurgeryTherapeuticsTraumaUrologyMiscellaneous